SCHEMBL22663689

SCHEMBL22663689

CN1C(=O)c2ccccc2Nc2nc(Nc3ccc(C(=O)O)c(C(F)(F)F)c3)ncc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NUAK1 O60285 2/20 0.45
▸ GSK3A P49840 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ DCLK1 O15075 4/20 0.41
▸ LRRK2 Q5S007 3/20 0.40
▸ PIK3CD O00329 2/20 0.40
▸ AURKA O14965 2/20 0.40
▸ PIK3C2G O75747 2/20 0.40
▸ PIK3CG P48736 2/20 0.40
▸ AURKB Q96GD4 2/20 0.40
▸ PTK2B Q14289 2/20 0.40
▸ WEE1 P30291 2/20 0.40
▸ MAPK7 Q13164 1/20 0.40
▸ PTK2 Q05397 1/20 0.40
▸ ULK1 O75385 4/20 0.40
▸ TNK2 Q07912 3/20 0.39
▸ TAS2R14 Q9NYV8 1/20 0.38
▸ SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16065843 0.84 NUAK1 (0.63) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL21938134 0.76 DCLK1 (0.68) DCLK1LRRK2PIK3CDAURKAPIK3C2G
SCHEMBL20628525 0.75 AURKA (0.69) DCLK1LRRK2PIK3CDAURKAPIK3C2G
SCHEMBL21938547 0.75 PIK3CD (0.70) GSK3AGSK3BDCLK1LRRK2PIK3CD
SCHEMBL10098750 0.73 NUAK1 (0.79) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL17465858 0.72 NUAK1 (0.67) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL22605998 0.71 NUAK1 (0.68) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL16065850 0.70 LRRK2 (0.65) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL20628496 0.69 DCLK1 (0.38) NUAK1DCLK1LRRK2PIK3CDAURKA
SCHEMBL10098751 0.68 NUAK1 (0.62) NUAK1GSK3BDCLK1LRRK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3738964-A1 PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS Dana Farber Cancer Institute, Inc. (US) 2020-11-18 — — EP disclosed
Send feedback